Interrupting HIV

Emily BurkeBiologics, Clinical Trials, Drug Development, Drug Targets, Genomics, HIV, Mechanism of Action, Monoclonal Antibodies, Ribonucleic Acid (RNA), Small Molecule Drugs, The WEEKLY

Therapies In HIV Pipeline Medicine has made gigantic strides in understanding and treating the human immunodeficiency virus (HIV) since its emergence in the early 1980s. Thanks to robust drug discovery efforts, today HIV is managed as a chronic disease instead of the death sentence of years past. The secret to HIV’s infectious success lies in its high mutation rate. Developing drug resistance over … Read More

Dodging Another Ebola Outbreak

Emily BurkeBiotech Basics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Ebola, Genetics, HIV, The WEEKLY

Ebola Finally Meets Its Match The headlining Ebola crisis of last summer devastated West Africa, marking the largest outbreak since the discovery of the disease in 1976. The glaring lack of a treatment or vaccine caused the virus to quickly spread within Guinea, Sierra Leone, and Nigeria. A small number of infected healthcare workers were able to receive an experimental antibody known as Zmapp … Read More

A Drop Of Biotech

Emily BurkeCancer, Clinical Trials, Cocktail Fodder, Diagnostics, Drug Development, Genomics, HIV, Orphan Disease, Orphan Drugs, The WEEKLY

Basics of Blood Disorders Blood is the carrier of a multitude of fundamental body processes—responsible for delivering vital nutrients/oxygen and for removing wastes. Like the highway exchange feeding a city of life, blood is simply essential. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of blood related diseases is known as hematology. This single therapeutic area covers a broad range … Read More

What The Heck Is qRT-PCR Diagnostics?

Emily BurkeBiotech Basics, Cancer, Cocktail Fodder, Deoxyribonucleic Acid (DNA), Diagnostics, Easily Confused, Genetics, Genomics, HIV, Ribonucleic Acid (RNA), The WEEKLY

From Impossible to possible The genetics of cancer has progressed from the impossible to a multifaceted mountain of possible. Comprehensive projects in whole genome sequencing and tumor genome sequencing are providing data to unravel the genetic predispositions of cancer. The other half of possible lies in quantitative PCR. This platform technology can identify types of cancer, effective therapeutics, and aggressiveness of the … Read More

Ready. Set. CRISPR.

Emily BurkeBiotech Basics, Business of Biotech, Cancer, Deoxyribonucleic Acid (DNA), Easily Confused, Genetics, Genomics, HIV, Ribonucleic Acid (RNA), The WEEKLY

CRISPR/CAS9 TECHNOLOGY BUILDS UP STEAM The world definitely weighed in after Chinese scientists published a paper detailing the use of CRISPR/Cas9 to edit nonviable human embryo genomes. While the embryos used were never intended to become a living human being, this controversial milestone created a firestorm of opinion. Tweets, blogs, and mainstream news stories were abuzz about the opening of Pandora’s box. … Read More

The Power Of Oncolytic Viruses

Emily BurkeBiologics, Cancer, Clinical Trials, Cocktail Fodder, Drug Development, Drug Targets, HIV, Mechanism of Action, The WEEKLY

HBO shines light on novel immunotherapies HBO’s Vice news program selected a few promising technologies from the immunotherapy pipeline to feature in its Killing Cancer episode. Vice’s heartrending human interest stories illustrated the potential of three different developmental drugs: An oncolytic measles virus battling myeloma.  An oncolytic adenovirus fighting a brain tumor. An engineered human immunodeficiency virus knocking out childhood leukemia.  While this program has generated buzz around … Read More

It’s A Great Time To Be In Biotech

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Approvals, Drug Development, Drug Targets, FDA, Genomics, HIV, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

It’s a great time to be in biotech—new therapeutics are breaking ground faster than we can say “monoclonal antibody” and the technologies behind them are heavy with promise and potential. Our mission is to keep your industry knowledge up to date and the WEEKLY is here to give you a smart primer on the basics. Below we have outlined several … Read More

Curing Hepatitis C

Emily BurkeBiologics, Business of Biotech, Cancer, Deoxyribonucleic Acid (DNA), Drug Approvals, Drug Targets, FDA, HIV, Mechanism of Action, Ribonucleic Acid (RNA), Small Molecule Drugs, The WEEKLY

The biotech industry gets its fair share of criticism. Take for example HBO’s John Oliver shining his light on biopharma last week and proclaiming drug companies are like high school boyfriends: more interested in getting into patients’ bodies than actually being effective once they’re inside. That soundbite prompted us at the WEEKLY to wonder: Is a 90% cure rate for a disease afflicting … Read More

Designer Genes: An Introduction To Genome-Editing

Emily BurkeBiologics, Biotech Basics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Targets, Genetics, Genomics, HIV, Mechanism of Action, Ribonucleic Acid (RNA), The WEEKLY

Five years ago, altering an individual’s genome would have been labeled unimaginable. Fast forward to today and one of the hottest new developments in biotech is genome-editing—the ability to selectively disable or edit the sequence of specific genes. In this WEEKLY we will compare and contrast the different genome-editing platforms in development and discover how close we are to a clinical reality. Got Gaps in Your … Read More

Squeezing The Juice Out Of Drug Metabolism

Emily BurkeCardiovascular Disease, Drug Targets, HIV, Mechanism of Action, Small Molecule Drugs, Term of the Week, The WEEKLY

When popping a pill, we seldom think about what happens next—to the pill, or even to our bodies. We assume the body welcomes any extra help to fix the problem, but the reaction is quite contrary. A swallowed pill (small molecule drug) is instantly labeled by our body as foreign and the reaction of our body is to immediately get … Read More

Playing Detective With Checkpoint Therapies

Emily BurkeCancer, Clinical Trials, Cocktail Fodder, Drug Development, Drug Targets, HIV, Mechanism of Action, Term of the Week, The WEEKLY

PLAYING DETECTIVE WITH CHECKPOINT THERAPIES Over the past two weeks, we have discussed cancer immunotherapies that involve training T-cells (the detective warriors of our immune system) into seeking and destroying cancer cells. This week, we will take a look into another approach that has been creating a lot of recent excitement: checkpoint inhibitor drugs. Simply put, investigators believe they have … Read More